Bladder cancer is the most frequent among the urothelial tumors, and it is responsible for about 2% of all cancer mortality worldwide. The mainstay of chemotherapy treatment, both for muscle-invasive and metastatic disease, is cisplatin-based regimens. In recent years, ground-breaking results have been achieved with immunotherapy, which have led to important breakthroughs in the bladder cancer treatment scenario, with the approval of several new agents. New insights derive from a greater characterization of the tumor genome, which could lead to developing new therapies, more personalized, in the near future.
Urologia 2017; 84(3): 130 - 141
Article Type: REVIEW
AuthorsGabriella Del Bene, Cora N. Sternberg
- • Accepted on 09/03/2017
- • Available online on 14/06/2017
- • Published in print on 01/08/2017
This article is available as full text PDF.
- Del Bene, Gabriella [PubMed] [Google Scholar] 1, 2, * Corresponding Author (firstname.lastname@example.org)
- Sternberg, Cora N. [PubMed] [Google Scholar] 1
Department of Medical Oncology, San Camillo Forlanini Hospital, Padiglione Flajani, Rome - Italy
Department of Experimental Medicine, “La Sapienza” University, Rome - Italy